Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

相似書籍

• Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium
  由: Villaruz, Liza C., et al.
  出版: (2014)
• Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium experience
  由: Sholl, Lynette M., et al.
  出版: (2015)
• Waxing and waning of MET amplification in EGFR mutated NSCLC in response to presence and absence of erlotinib selection pressure
  由: Womack, Joel P., et al.
  出版: (2015)
• The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations – the Lung Cancer Mutation Consortium (LCMC2)
  由: Aisner, Dara L., et al.
  出版: (2017)
• Diagnostic Assays for Identification of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer
  由: Weickhardt, Andrew J., et al.
  出版: (2012)